Mixture for transdermal delivery of low and high molecular weight compounds
View Patent ↗The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed.
1. A method of reducing the appearance of a varicose vein or a spider vein comprising:
providing a transdermal delivery system that comprises an ethoxylated oil containing between 10 and 19 ethoxylations/molecule; and
applying said transdermal delivery system to said varicose vein or said spider vein.
2. A method of reducing the appearance of a stretch mark comprising:
providing a transdermal delivery system that comprises an ethoxylated oil containing between 10 and 19 ethoxylations/molecule; and
applying said transdermal delivery system to said stretch mark.
3. The method of claim 2 , wherein the transdermal delivery system further comprises Kayuuputih Eucalyptus oil.
4. A transdermal delivery system comprising:
an ethoxylated oil containing between 10 and 19 ethoxylations/molecule; and
Kayuuputih Eucalyptus oil mixed with said ethoxylated oil.
5. A method of reducing the appearance of a skin discoloration comprising:
providing a transdermal delivery system that comprises an ethoxylated oil containing between 10 and 19 ethoxylations/molecule and a skin brightener; and
applying said transdermal delivery system to said skin discoloration.
6. The method of claim 5 , wherein the skin brightener is a melanin inhibitor.
7. The method of claim 5 , wherein the skin brightener is a tyrosinase inhibitor.
8. The method of claim 5 , wherein the skin brightener is Melaslow.
9. The method of claim 5 , wherein the skin brightener is Etioline.
10. A transdermal delivery system comprising:
an ethoxylated oil containing between 10 and 19 ethoxylations/molecule; and
a skin brightener mixed with said ethoxylated oil.
11. The transdermal delivery system of claim 10 , wherein the skin brightener is a melanin inhibitor.
12. The transdermal delivery system of claim 10 , wherein the skin brightener is a tyrosinase inhibitor.
13. The transdermal delivery system of claim 10 , wherein the skin brightener is Melaslow.
14. The transdermal delivery system of claim 10 , wherein the skin brightener is Etioline.
15. A method of providing a fragrance comprising:
providing a transdermal delivery system that comprises an ethoxylated oil containing between 10 and 19 ethoxylations/molecule and a fragrance; and
applying said transdermal delivery system to the skin of an individual.
16. A transdermal delivery system comprising:
an ethoxylated oil containing between 10 and 19 ethoxylations/molecule; and
a fragrance mixed with said ethoxylated oil.
17. A method of facilitating recovery from a burn comprising:
providing a transdermal delivery system that comprises an ethoxylated oil containing between 10 and 19 ethoxylations/molecule; and
applying said transdermal delivery system to a burn.
18. The method of claim 1 , wherein said ethoxylated oil contains 16 ethoxylations/molecule.
19. The method of claim 1 , wherein said ethoxylated oil comprises an ethoxylated macadamia nut oil.
20. The method of claim 1 , wherein said ethoxylated oil comprises an ethoxylated meadow foam oil.
21. The method of claim 1 , wherein the transdermal delivery system further comprises water.
22. The method of claim 1 , wherein the transdermal delivery system further comprises an alcohol.
23. The method of claim 2 , wherein said ethoxylated oil contains 16 ethoxylations/molecule.
24. The method of claim 2 , wherein said ethoxylated oil comprises an ethoxylated macadamia nut oil.
25. The method of claim 2 , wherein said ethoxylated oil comprises an ethoxylated meadow foam oil.
26. The method of claim 2 , wherein the transdermal delivery system further comprises water.
27. The method of claim 2 , wherein the transdermal delivery system further comprises an alcohol.
28. The method of claim 2 , wherein the transdermal delivery system further comprises a delivered agent.
29. The transdermal delivery system of claim 4 , wherein said ethoxylated oil contains 16 ethoxylations/molecule.
30. The transdermal delivery system of claim 4 , wherein said ethoxylated oil comprises an ethoxylated macadamia nut oil.
31. The transdermal delivery system of claim 4 , wherein said ethoxylated oil comprises an ethoxylated meadow foam oil.
32. The transdermal delivery system of claim 4 , further comprising water.
33. The transdermal delivery system of claim 4 , further comprising an alcohol.
34. The transdermal delivery system of claim 4 , wherein said delivered agent is less than 1,000 daltons.
35. The transdermal delivery system of claim 4 , wherein said delivered agent is 1,000 daltons or greater.
36. The transdermal delivery system of claim 4 , wherein said delivered agent is 10,000 daltons or greater.
37. The transdermal delivery system of claim 4 , wherein said delivered agent is 100,000 daltons or greater.
38. The transdermal delivery system of claim 4 , wherein said delivered agent is 300,000 daltons or greater.
39. The transdermal delivery system of claim 4 , wherein said delivered agent is 500,000 daltons or greater.
40. The transdermal delivery system of claim 4 , wherein said delivered agent is less than 2,000,000 daltons.
41. The transdermal delivery system of claim 4 , wherein said delivered agent is a steroid.
42. The transdermal delivery system of claim 4 , wherein said delivered agent is an antiviral compound.
43. The transdermal delivery system of claim 4 , wherein said delivered agent is a nucleic acid.
44. The transdermal delivery system of claim 4 , wherein said delivered agent is a peptide.
45. The transdermal delivery system of claim 44 , wherein said peptide is less than 1,000 daltons.
46. The transdermal delivery system of claim 44 , wherein said peptide is 1,000 daltons or more but less than 2,000,000 daltons.
47. The transdermal delivery system of claim 44 , wherein said peptide is 100,000 daltons or greater.
48. The transdermal delivery system of claim 44 , wherein said peptide is 300,000 daltons or greater.
49. The transdermal delivery system of claim 44 , wherein said peptide is 500,000 daltons or greater.
50. The transdermal delivery system of claim 4 , further comprising a second delivered agent, wherein said second delivered agent is a non-steroidal anti inflammatory drug (NSAID).
51. The transdermal delivery system of claim 50 , wherein said non-steroidal anti inflammatory drug (NSAID) is selected from the group consisting of ibuprofen (2-(isobutylphenyl)-propionic acid); methotrexate (N-[4-(2, 4 diamino 6-pteridinyl-methyl]methylamino]benzoyl)-L-glutamic acid); aspirin (acetylsalicylic acid); salicylic acid; diphenhydramine (2-(diphenylmethoxy)-NN-dimethylethylamine hydrochloride); naproxen (2-naphthaleneacetic acid, 6-methoxy-9-methyl-, sodium salt, (−)); phenylbutazone (4-butyl-1,2-diphenyl-3,5-pyrazolidinedione); sulindac-(2)-5-fuoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene-]-1H-indene-3-acetic acid; diflunisal (2′,4′, -difluoro-4-hydroxy-3-biphenylcarboxylic acid; piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-2-carboxamide 1,1-dioxide, an oxicam; indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-H-indole-3-acetic acid); meclofenamate sodium (N-(2,6-dichloro-m-tolyl) anthranilic acid, sodium salt, monohydrate); ketoprofen (2-(3-benzoylphenyl)-propionic acid; tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl-1H-pyrrole-2-acetate dihydrate); diclofenac sodium (2-[(2,6-dichlorophenyl)amino]benzeneatic acid, monosodium salt); hydroxychioroquine sulphate (2-{[4-[(7-chloro-4-quinolyl) amino]pentyl]ethylamino}ethanol sulfate (1:1); penicillamine (3-mercapto-D-valine); flurbiprofen ([1,1-biphenyl]-4-acetic acid, 2-fluoro-aphamethyl-, (+−)); cetodolac (1-8-diethyl-13,4,9,tetra hydropyrano-[3-4-13]indole-1-acetic acid; mefenamic acid (N-(2,3-xylyl)anthranilic acid; and diphenhydramine hydrochloride (2-diphenyl methoxy-N,N-di-methylethamine hydrochloride).
52. The transdermal delivery system of claim 4 , wherein said delivered agent is a collagen or fragment thereof.
53. The transdermal delivery system of claim 52 , wherein said collagen has an approximate average molecular weight from about 2,000 daltons to about 500,000 daltons.
54. The transdermal delivery system of claim 52 , wherein the amount of said collagen or fragment thereof by weight or volume is 0.1% to 50.0%.
55. The transdermal delivery system of claim 52 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 2,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 50.0%.
56. The transdermal delivery system of claim 52 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 300,000 daltons and the therapeutically effective amount is 0.1% to 2.0%.
57. The transdermal delivery system of claim 52 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 500,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 4.0%.
58. A method of transdermal delivery of a delivered agent comprising:
identifying a subject in need of transdermal delivery of a delivered agent; and
providing said subject a transdermal delivery system according to claim 4 .
59. The method of claim 58 , wherein said ethoxylated oil contains 16 ethoxylations/molecule.
60. The method of claim 58 , wherein said ethoxylated oil comprises an ethoxylated macadamia nut oil.
61. The method of claim 58 , wherein said ethoxylated oil comprises an ethoxylated meadow foam oil.
62. The method of claim 58 , further comprising water.
63. The method of claim 58 , further comprising an alcohol.
64. The method of claim 58 , wherein said delivered agent is less than 1,000 daltons.
65. The method of claim 58 , wherein said delivered agent is 1,000 daltons or greater.
66. The method of claim 58 , wherein said delivered agent is 10,000 daltons or greater.
67. The method of claim 58 , wherein said delivered agent is 100,000 daltons or greater.
68. The method of claim 58 , wherein said delivered agent is 300,000 daltons or greater.
69. The method of claim 58 , wherein said delivered agent is 500,000 daltons or greater.
70. The method of claim 58 , wherein said delivered agent is less than 2,000,000 daltons.
71. The method of claim 58 , wherein said delivered agent is a steroid.
72. The method of claim 58 , wherein said delivered agent is an antiviral compound.
73. The method of claim 58 , wherein said delivered agent is a nucleic acid.
74. The method of claim 58 , wherein said delivered agent is a peptide.
75. The method of claim 74 , wherein said peptide is less than 1,000 daltons.
76. The method of claim 74 , wherein said peptide is 1,000 daltons or more but less than 2,000,000 daltons.
77. The method of claim 74 , wherein said peptide is 100,000 daltons or greater.
78. The method of claim 74 , wherein said peptide is 300,000 daltons or greater.
79. The method of claim 74 , wherein said peptide is 500,000 daltons or greater.
80. The method of claim 58 , further comprising a second delivered agent, wherein said second delivered agent is a non-steroidal anti inflammatory drug (NSAID).
81. The method of claim 80 , wherein said non-steroidal anti inflammatory drug (NSAID) is selected from the group consisting of ibuprofen (2-(isobutylphenyl)-propionic acid); methotrexate (N-[4-(2,4 diamino 6-pteridinyl-methyl]methylamino]benzoyl)-L-glutamic acid); aspirin (acetylsalicylic acid); salicylic acid; diphenhydramine (2-(diphenylmethoxy)-NN-dimethylethylamine hydrochloride); naproxen (2-naphthaleneacetic acid, 6-methoxy-9-methyl-, sodium salt, (−)); phenylbutazone (4-butyl -1,2-diphenyl-3,5-pyrazolidinedione); sulindac-(2)-5-fuoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene-]-1H-indene-3-acetic acid; diflunisal (2′,4′-difluoro-4-hydroxy-3-biphenylcarboxylic acid; piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1, 2-benzothiazine-2-carboxamide 1,1-dioxide, an oxicam; indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-H-indole-3-acetic acid); meclofenamate sodium (N -(2,6-dichloro-m-tolyl) anthranilic acid, sodium salt, monohydrate); ketoprofen (2-(3-benzoylphenyl)-propionic acid; tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl -1H-pyrrole-2-acetate dihydrate); diclofenac sodium (2-[(2,6-dichlorophenyl)amino]benzeneatic acid, monosodium salt); hydroxychloroquine sulphate (2-{[4-[(7-chloro-4-quinolyl) amino]pentyl]ethylamino}ethanol sulfate (1:1); penicillamine (3-mercapto-D -valine); flurbiprofen ([1,1-biphenyl]-4-acetic acid, 2-fluoro-alphamethyl-, (+−)); cetodolac (1-8-diethyl-13,4,9, tetra hydropyrano-[3-4-13]indole-1-acetic acid; mefenamic acid (N -(2,3-xylyl)anthranilic acid; and diphenhydramine hydrochloride (2-diphenyl methoxy-N, N-di-methylethamine hydrochloride).
82. The method of claim 58 , wherein said delivered agent is a collagen or fragment thereof.
83. The method of claim 82 , wherein said collagen has an approximate average molecular weight from about 2,000 daltons to about 500,000 daltons.
84. The method of claim 82 , wherein the amount of said collagen or fragment thereof by weight or volume is 0.1% to 50.0%.
85. The method of claim 82 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 2,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 50.0%.
86. The method of claim 82 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 300,000 daltons and the therapeutically effective amount is 0.1% to 2.0%.
87. The method of claim 82 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 500,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 4.0%.
88. The method of claim 5 , wherein said ethoxylated oil contains 16 ethoxylations/molecule.
89. The method of claim 5 , wherein said ethoxylated oil comprises an ethoxylated macadamia nut oil.
90. The method of claim 5 , wherein said ethoxylated oil comprises an ethoxylated meadow foam oil.
91. The method of claim 5 , further comprising water.
92. The method of claim 5 , further comprising an alcohol.
93. The method of claim 5 , further comprising a second delivered agent, wherein said second delivered agent is a peptide.
94. The method of claim 93 , wherein said peptide is less than 1,000 daltons.
95. The method of claim 93 , wherein said peptide is 1,000 daltons or more but less than 2,000,000 daltons.
96. The method of claim 93 , wherein said peptide is 100,000 daltons or greater.
97. The method of claim 93 , wherein said peptide is 300,000 daltons or greater.
98. The method of claim 93 , wherein said peptide is 500,000 daltons or greater.
99. The method of claim 93 , wherein said second delivered agent is a collagen or fragment thereof.
100. The method of claim 99 , wherein said collagen has an approximate average molecular weight from about 2,000 daltons to about 500,000 daltons.
101. The method of claim 99 , wherein the amount of said collagen or fragment thereof by weight or volume is 0.1% to 5 0.0%.
102. The method of claim 99 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 2,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 50.0%.
103. The method of claim 99 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 300,000 daltons and the therapeutically effective amount is 0.1% to 2.0%.
104. The method of claim 99 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 500,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 4.0%.
105. The transdermal delivery system of claim 10 , wherein said ethoxylated oil contains 16 ethoxylations/molecule.
106. The transdermal delivery system of claim 10 , wherein said ethoxylated oil comprises an ethoxylated macadamia nut oil.
107. The transdermal delivery system of claim 10 , wherein said ethoxylated oil comprises an ethoxylated meadow foam oil.
108. The transdermal delivery system of claim 10 , further comprising water.
109. The transdermal delivery system of claim 10 , further comprising an alcohol.
110. The transdermal delivery system of claim 10 , further comprising a second delivered agent, wherein said second delivered agent is a peptide.
111. The transdermal delivery system of claim 110 , wherein said peptide is less than 1,000 daltons.
112. The transdermal delivery system of claim 110 , wherein said peptide is 1,000 daltons or more but less than 2,000,000 daltons.
113. The transdermal delivery system of claim 112 , wherein said peptide is 100,000 daltons or greater.
114. The transdermal delivery system of claim 112 , wherein said peptide is 300,000 daltons or greater.
115. The transdermal delivery system of claim 112 , wherein said peptide is 500,000 daltons or greater.
116. The transdermal delivery system of claim 112 , wherein said second delivered agent is a collagen or fragment thereof.
117. The transdermal delivery system of claim 116 , wherein said collagen has an approximate average molecular weight from about 2,000 daltons to about 500,000 daltons.
118. The transdermal delivery system of claim 116 , wherein the amount of said collagen or fragment thereof by weight or volume is 0.1% to 50.0%.
119. The transdermal delivery system of claim 116 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 2,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 5 0.0%.
120. The transdermal delivery system of claim 116 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 300,000 daltons and the therapeutically effective amount is 0.1% to 2.0%.
121. The transdermal delivery system of claim 116 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 500,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 4.0%.
122. The method of claim 15 , wherein said ethoxylated oil contains 16 ethoxylations/molecule.
123. The method of claim 15 , wherein said ethoxylated oil comprises an ethoxylated macadamia nut oil.
124. The method of claim 15 , wherein said ethoxylated oil comprises an ethoxylated meadow foam oil.
125. The method of claim 15 , further comprising water.
126. The method of claim 15 , further comprising an alcohol.
127. The method of claim 15 , further comprising a delivered agent other than said fragrance.
128. The method of claim 127 , wherein said delivered agent is less than 1,000 daltons.
129. The method of claim 127 , wherein said delivered agent is 1,000 daltons or greater.
130. The method of claim 127 , wherein said delivered agent is 10,000 daltons or greater.
131. The method of claim 127 , wherein said delivered agent is 100,000 daltons or greater.
132. The method of claim 127 , wherein said delivered agent is 300,000 daltons or greater.
133. The method of claim 127 , wherein said delivered agent is 500,000 daltons or greater.
134. The method of claim 127 , wherein said delivered agent is less than 2,000,000 daltons.
135. The method of claim 127 , wherein said delivered agent is a steroid.
136. The method of claim 127 , wherein said delivered agent is an antiviral compound.
137. The method of claim 127 , wherein said delivered agent is a nucleic acid.
138. The method of claim 127 , wherein said delivered agent is a peptide.
139. The method of claim 138 , wherein said peptide is less than 1,000 daltons.
140. The method of claim 138 , wherein said peptide is 1,000 daltons or more but less than 2,000,000 daltons.
141. The method of claim 138 , wherein said peptide is 100,000 daltons or greater.
142. The method of claim 138 , wherein said peptide is 300,000 daltons or greater.
143. The method of claim 138 , wherein said peptide is 500,000 daltons or greater.
144. The method of claim 127 , wherein said delivered agent is a non-steroidal anti inflammatory drug (NSAID).
145. The method of claim 144 , wherein said non-steroidal anti inflammatory drug (NSAID) is selected from the group consisting of ibuprofen (2-(isobutylphenyl)-propionic acid); methotrexate (N-[4-(2,4 diamino 6-pteridinyl-methyl]methylamino]benzoyl)-L-glutamic acid); aspirin (acetylsalicylic acid); salicylic acid; diphenhydramine (2-(diphenylmethoxy)-NN-dimethylethylamine hydrochloride); naproxen (2-naphthaleneacetic acid, 6-methoxy-9-methyl-, sodium salt, (−)); phenylbutazone (4-butyl -1,2-diphenyl-3,5-pyrazolidinedione); sulindac-(2)-5-fuoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene-]-1H-indene-3-acetic acid; diflunisal (2′,4′, -difluoro-4-hydroxy-3-biphenylcarboxylic acid; piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1, 2-benzothiazine-2-carboxamide 1,1-dioxide, an oxicam; indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-H-indole-3-acetic acid); meclofenamate sodium (N -(2,6-dichloro-m-tolyl) anthranilic acid, sodium salt, monohydrate); ketoprofen (2-(3-benzoylphenyl)-propionic acid; tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl-1H-pyrrole-2-acetate dihydrate); diclofenac sodium (2-[(2,6-dichlorophenyl)amino]benzeneatic acid, monosodium salt); hydroxychloroquine sulphate (2-{[4-[(7-chloro-4-quinolyl) amino]pentyl]ethylamino}ethanol sulfate (1:1); penicillamine (3-mercapto-D-valine); flurbiprofen ([1,1-biphenyl]-4-acetic acid, 2-fluoro-alphamethyl-, (+−)); cetodolac (1-8-diethyl-13,4,9, tetra hydropyrano-[3-4-13]indole-1-acetic acid; mefenamic acid (N-(2,3-xylyl)anthranilic acid; and diphenhydramine hydrochloride (2-diphenyl methoxy-N, N-di-methylethamine hydrochloride).
146. The method of claim 127 , wherein said delivered agent is a collagen or fragment thereof.
147. The method of claim 146 , wherein said collagen has an approximate average molecular weight from about 2,000 daltons to about 500,000 daltons.
148. The method of claim 146 , wherein the amount of said collagen or fragment thereof by weight or volume is 0.1% to 50.0%.
149. The method of claim 146 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 2,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 50.0%.
150. The method of claim 146 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 300,000 daltons and the therapeutically effective amount is 0.1% to 2.0%.
151. The method of claim 146 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 500,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 4.0%.
152. The method of claim 15 , wherein said fragrance is selected from the group consisting of lemon, lavender, orange, tangerine, and Y-Lang Y-Lang.
153. The transdermal delivery system of claim 16 , wherein said ethoxylated oil contains 16 ethoxylations/molecule.
154. The transdermal delivery system of claim 16 , wherein said ethoxylated oil comprises an ethoxylated macadamia nut oil.
155. The transdermal delivery system of claim 16 , wherein said ethoxylated oil comprises an ethoxylated meadow foam oil.
156. The transdermal delivery system of claim 16 , further comprising water.
157. The transdermal delivery system of claim 16 , further comprising an alcohol.
158. The transdermal delivery system of claim 16 , further comprising a delivered agent other than said fragrance.
159. The transdermal delivery system of claim 158 , wherein said delivered agent is less than 1,000 daltons.
160. The transdermal delivery system of claim 158 , wherein said delivered agent is 1,000 daltons or greater.
161. The transdermal delivery system of claim 158 , wherein said delivered agent is 10,000 daltons or greater.
162. The transdermal delivery system of claim 158 , wherein said delivered agent is 100,000 daltons or greater.
163. The transdermal delivery system of claim 158 , wherein said delivered agent is 300,000 daltons or greater.
164. The transdermal delivery system of claim 158 , wherein said delivered agent is 500,000 daltons or greater.
165. The transdermal delivery system of claim 158 , wherein said delivered agent is less than 2,000,000 daltons.
166. The transdermal delivery system of claim 158 , wherein said delivered agent is a steroid.
167. The transdermal delivery system of claim 158 , wherein said delivered agent is an antiviral compound.
168. The transdermal delivery system of claim 158 , wherein said delivered agent is a nucleic acid.
169. The transdermal delivery system of claim 158 , wherein said delivered agent is a peptide.
170. The transdermal delivery system of claim 169 , wherein said peptide is less than 1,000 daltons.
171. The transdermal delivery system of claim 169 , wherein said peptide is 1,000 daltons or more but less than 2,000,000 daltons.
172. The transdermal delivery system of claim 169 , wherein said peptide is 100,000 daltons or greater.
173. The transdermal delivery system of claim 169 , wherein said peptide is 300,000 daltons or greater.
174. The transdermal delivery system of claim 169 , wherein said peptide is 500,000 daltons or greater.
175. The transdermal delivery system of claim 158 , wherein said delivered agent is a non-steroidal anti inflammatory drug (NSAID).
176. The transdermal delivery system of claim 175 , wherein said non-steroidal anti inflammatory drug (NSAID) is selected from the group consisting of ibuprofen (2-(isobutylphenyl)-propionic acid); methotrexate (N-[4-(2,4 diamino 6-pteridinyl -methyl]methylamino]benzoyl)-L-glutamic acid); aspirin (acetylsalicylic acid); salicylic acid; diphenhydramine (2-(diphenylmethoxy)-NN-dimethylethylamine hydrochloride); naproxen (2-naphthaleneacetic acid, 6-methoxy-9-methyl-, sodium salt, (−)); phenylbutazone (4-butyl-1,2-diphenyl-3,5-pyrazolidinedione); sulindac-(2)-5-fuoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene-]-1H-indene-3-acetic acid; diflunisal (2′,4′-difluoro-4-hydroxy-3-biphenylcarboxylic acid; piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-2-carboxamide 1,1-dioxide, an oxicam; indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-H-indole-3-acetic acid); meclofenamate sodium (N-(2,6-dichloro-m-tolyl) anthranilic acid, sodium salt, monohydrate); ketoprofen (2-(3-benzoylphenyl)-propionic acid; tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl-1H-pyrrole-2-acetate dihydrate); diclofenac sodium (2-[(2,6-dichlorophenyl)amino]benzeneatic acid, monosodium salt); hydroxychloroquine sulphate (2-{[4-[(7-chloro-4-quinolyl) amino]pentyl]ethylamino}ethanol sulfate (1:1); penicillamine (3-mercapto-D-valine); flurbiprofen ([1,1-biphenyl]-4-acetic acid, 2-fluoro-aiphamethyl-, (+−)); cetodolac (1-8-diethyl-13,4,9, tetra hydropyrano-[3-4-13]indole-1-acetic acid; mefenamic acid (N-(2,3-xylyl)anthranilic acid; and diphenhydramine hydrochloride (2-diphenyl methoxy-N,N-di-methylethamine hydrochloride).
177. The transdermal delivery system of claim 158 , wherein said delivered agent is a collagen or fragment thereof.
178. The transdermal delivery system of claim 177 , wherein said collagen has an approximate average molecular weight from about 2,000 daltons to about 500,000 daltons.
179. The transdermal delivery system of claim 178 , wherein the amount of said collagen or fragment thereof by weight or volume is 0.1% to 50.0%.
180. The transdermal delivery system of claim 178 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 2,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 50.0%.
181. The transdermal delivery system of claim 178 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 300,000 daltons and the therapeutically effective amount is 0.1% to 2.0%.
182. The transdermal delivery system of claim 178 , wherein said collagen or fragment thereof has an approximate average molecular weight of about 500,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 4.0%.
183. The transdermal delivery system of claim 16 , wherein said fragrance is selected from the group consisting of lemon, lavender, orange, tangerine, and Y-Lang Y-Lang.
184. The method of claim 17 , wherein said ethoxylated oil contains 16 ethoxylations/molecule.
185. The method of claim 17 , wherein said ethoxylated oil comprises an ethoxylated macadamia nut oil.
186. The method of claim 17 , wherein said ethoxylated oil comprises an ethoxylated meadow foam oil.
187. The method of claim 17 , wherein the transdermal delivery system further comprises water.
188. The method of claim 17 , wherein the transdermal delivery system further comprises an alcohol.